AMGEN INC AMGN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, AMGEN INC reported revenue across 17 products and services; the largest, Product, was $35.1B (+9.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$35.1Bshare n/a+9.7% yoy
- Other Products$7.26Bshare n/a+29.0% yoy
- Prolia$4.41Bshare n/a+0.9% yoy
- Repatha$3.02Bshare n/a+35.7% yoy
- Otezla$2.27Bshare n/a+6.5% yoy
- Enbrel$2.23Bshare n/a-32.9% yoy
- EVENITY$2.1Bshare n/a+34.4% yoy
- Xgeva$2.08Bshare n/a-6.3% yoy
- +9 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$26.4B71.9%+10.7% yoy
- Outside the United States$10.3B28.1%+8.1% yoy
Members sum to the consolidated $36.8B for this period.
- Product$8.22Bshare n/a+4.4% yoy
- Other Products$1.53Bshare n/a+3.6% yoy
- Repathaevolocumab$876Mshare n/a+33.5% yoy
- Prolia$727Mshare n/a-33.8% yoy
- EVENITY$562Mshare n/a+27.1% yoy
- TEPEZZA$490Mshare n/a+28.6% yoy
- +13 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.